At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 20 enrolled
Drug / intervention
Terlipressin +1 moredrug
Likely dose
Terlipressin 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Noradrenalin vs Terlipressin in Patients With Hepatorenal Syndrome.A Prospective, Randomized Study
In Brief
A Phase 3 clinical trial evaluating Terlipressin and Noradrenalin for Hepatorenal Syndrome. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether noradrenalin is as effective and safe as terlipressin in the treatment of hepatorenal syndrome
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatorenal Syndrome
CountriesItaly
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2006
Enrollment StartSep 2006
Primary CompletionSep 2007
TodayJul 2026
First PostedAug 31, 2006
Enrollment StartSep 1, 2006
Primary CompletionSep 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 19.8 years ago
Interventions
Terlipressindrug
1mg/4 h per day
Noradrenalindrug
0,1 mcg/kg/min